MX2022015146A - Tratamiento de la artritis reumatoide. - Google Patents

Tratamiento de la artritis reumatoide.

Info

Publication number
MX2022015146A
MX2022015146A MX2022015146A MX2022015146A MX2022015146A MX 2022015146 A MX2022015146 A MX 2022015146A MX 2022015146 A MX2022015146 A MX 2022015146A MX 2022015146 A MX2022015146 A MX 2022015146A MX 2022015146 A MX2022015146 A MX 2022015146A
Authority
MX
Mexico
Prior art keywords
rheumatoid arthritis
treating rheumatoid
inhibitor
therapeutically effective
effective dose
Prior art date
Application number
MX2022015146A
Other languages
English (en)
Spanish (es)
Inventor
Michael Louis Doyle
Gary L Schieven
Shailesh Dudhgaonkar
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2022015146A publication Critical patent/MX2022015146A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2022015146A 2020-06-22 2021-06-21 Tratamiento de la artritis reumatoide. MX2022015146A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202011026256 2020-06-22
PCT/US2021/038170 WO2021262561A1 (en) 2020-06-22 2021-06-21 Treating rheumatoid arthritis

Publications (1)

Publication Number Publication Date
MX2022015146A true MX2022015146A (es) 2023-01-11

Family

ID=76959071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015146A MX2022015146A (es) 2020-06-22 2021-06-21 Tratamiento de la artritis reumatoide.

Country Status (11)

Country Link
US (1) US20230310409A1 (https=)
EP (1) EP4168049A1 (https=)
JP (1) JP2023531944A (https=)
KR (1) KR20230027212A (https=)
CN (1) CN115768479A (https=)
AU (1) AU2021296150A1 (https=)
BR (1) BR112022025920A2 (https=)
CA (1) CA3183306A1 (https=)
IL (1) IL299147A (https=)
MX (1) MX2022015146A (https=)
WO (1) WO2021262561A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016356780A1 (en) * 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
US10071079B2 (en) * 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EP3853252A1 (en) * 2018-09-18 2021-07-28 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof

Also Published As

Publication number Publication date
CA3183306A1 (en) 2021-12-30
KR20230027212A (ko) 2023-02-27
JP2023531944A (ja) 2023-07-26
EP4168049A1 (en) 2023-04-26
CN115768479A (zh) 2023-03-07
WO2021262561A1 (en) 2021-12-30
BR112022025920A2 (pt) 2023-01-10
IL299147A (en) 2023-02-01
US20230310409A1 (en) 2023-10-05
AU2021296150A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
MX2022015146A (es) Tratamiento de la artritis reumatoide.
MX2022005994A (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
MX2024011142A (es) Tratamiento de neurofibromas cutaneos con mirdametinib.
MX2023002024A (es) Métodos de tratamiento con modulador de miosina.
ZA202310050B (en) Pharmaceutical composition for preventing or treating fibrosis
MX2022015760A (es) Inhibidor del receptor tipo toll 7 (tlr7) en combinacion con prednisolona o hidroxicloroquina para el tratamiento del lupus eritematoso cutaneo.
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
MX2023010314A (es) Terapia de combinación usando un inhibidor de malt1 y un inhibidor de btk.
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2022012923A (es) Inhibidores de trpc6 para tratar afecciones respiratorias.
IL318374A (en) Methods of administering nalbuphine
WO2022040369A8 (en) Methods for treating remitting multiple sclerosis
NZ793855A (en) Methods of treating pulmonary fibrosis
WO2022026622A3 (en) Treatment of viral diseases
PH12021553098A1 (en) Treatment for synucleinopathies
PH12022553502A1 (en) Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine
MX2024015758A (es) Metodos para el tratamiento del glioblastoma con profarmacos de riluzol
MX2024008476A (es) Metodos de tratamiento de la fibrosis pulmonar idiopatica con deupirfenidona.
MX2023002347A (es) Nuevas composiciones y métodos para el tratamiento de la fibrosis pulmonar.
WO2023019095A3 (en) Momelotinib combination therapy
MX2023009620A (es) Metodos terapeuticos.
MX2023011047A (es) Dc009 para el tratamiento de accidente cerebro-vascular isquemico agudo.
MX2025001316A (es) Tratamiento de la urticaria con inhibidores de la cinasa de janus (jak)
MX2023001410A (es) Composicion farmaceutica de corticosteroides intraarticulares para el control del dolor.